Trial Profile
Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema; Wet age-related macular degeneration
- Focus Therapeutic Use
- 13 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 13 Jan 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.
- 06 May 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.